Near-tetraploidy is associated with aggressive disease characteristics
| Characteristic . | Total, n = 297 . | Not tetraploid, n = 288 . | Tetraploid, n = 9 . | P . |
|---|---|---|---|---|
| Study, no. (%) | .25 | |||
| OSU-10032 | 48 (16) | 46 (16) | 2 (22) | |
| OSU-10053 | 68 (23) | 65 (23) | 3 (33) | |
| OSU-11133 | 145 (49) | 143 (50) | 2 (22) | |
| OSU-12024 | 36 (12) | 34 (12) | 2 (22) | |
| Monotherapy with ibrutinib, no. (%) | .43 | |||
| No | 68 (23) | 66 (23) | 3 (33) | |
| Yes | 229 (77) | 223 (77) | 6 (67) | |
| Age, y | .85 | |||
| Median | 65 | 65 | 64 | |
| Range | 26-91 | 26-91 | 52-79 | |
| Sex, no. (%) | .29 | |||
| Male | 211 (71) | 206 (72) | 5 (56) | |
| Female | 86 (29) | 82 (28) | 4 (44) | |
| Rai stage, no. (%) | .03 | |||
| 0/I/II | 101 (34) | 101 (35) | 0 (0) | |
| III/IV | 196 (66) | 187 (65) | 9 (100) | |
| LDH, U/L | .19 | |||
| Median | 220 | 220 | 227 | |
| Range | 96-1485 | 96-1485 | 142-765 | |
| No. of prior therapies | .12 | |||
| Median | 3 | 3 | 5 | |
| Range | 0-16 | 0-16 | 2-8 | |
| Gain of BCL6, no. (%) | .15 | |||
| No | 274 (92) | 267 (93) | 7 (78) | |
| Yes | 23 (8) | 21 (7) | 2 (22) | |
| Gain of CMYC, no. (%) | . | .09 | ||
| No | 235 (79) | 230 (80) | 5 (56) | |
| Yes | 62 (21) | 58 (20) | 4 (44) | |
| Trisomy 12, no. (%) | .05 | |||
| No | 245 (82) | 240 (83) | 5 (56) | |
| Yes | 52 (18) | 48 (17) | 4 (44) | |
| Del(13q), no. (%) | .75 | |||
| No | 145 (49) | 140 (49) | 5 (56) | |
| Yes | 152 (51) | 148 (51) | 4 (44) | |
| Del(11q), no. (%) | 1.00 | |||
| No | 214 (72) | 207 (72) | 7 (78) | |
| Yes | 83 (28) | 81 (28) | 2 (22) | |
| Del(17p), no. (%) | .03 | |||
| No | 177 (60) | 175 (61) | 2 (22) | |
| Yes | 120 (40) | 113 (39) | 7 (78) | |
| Complex karyotype, no. (%) | .01 | |||
| No | 119 (41) | 119 (42) | 0 (0) | |
| Yes | 172 (59) | 163 (58) | 9 (100) | |
| IGHV, no. (%) | .35 | |||
| Mutated | 53 (20) | 53 (21) | 0 (0) | |
| Unmutated | 212 (80) | 205 (79) | 7 (100) | |
| Characteristic . | Total, n = 297 . | Not tetraploid, n = 288 . | Tetraploid, n = 9 . | P . |
|---|---|---|---|---|
| Study, no. (%) | .25 | |||
| OSU-10032 | 48 (16) | 46 (16) | 2 (22) | |
| OSU-10053 | 68 (23) | 65 (23) | 3 (33) | |
| OSU-11133 | 145 (49) | 143 (50) | 2 (22) | |
| OSU-12024 | 36 (12) | 34 (12) | 2 (22) | |
| Monotherapy with ibrutinib, no. (%) | .43 | |||
| No | 68 (23) | 66 (23) | 3 (33) | |
| Yes | 229 (77) | 223 (77) | 6 (67) | |
| Age, y | .85 | |||
| Median | 65 | 65 | 64 | |
| Range | 26-91 | 26-91 | 52-79 | |
| Sex, no. (%) | .29 | |||
| Male | 211 (71) | 206 (72) | 5 (56) | |
| Female | 86 (29) | 82 (28) | 4 (44) | |
| Rai stage, no. (%) | .03 | |||
| 0/I/II | 101 (34) | 101 (35) | 0 (0) | |
| III/IV | 196 (66) | 187 (65) | 9 (100) | |
| LDH, U/L | .19 | |||
| Median | 220 | 220 | 227 | |
| Range | 96-1485 | 96-1485 | 142-765 | |
| No. of prior therapies | .12 | |||
| Median | 3 | 3 | 5 | |
| Range | 0-16 | 0-16 | 2-8 | |
| Gain of BCL6, no. (%) | .15 | |||
| No | 274 (92) | 267 (93) | 7 (78) | |
| Yes | 23 (8) | 21 (7) | 2 (22) | |
| Gain of CMYC, no. (%) | . | .09 | ||
| No | 235 (79) | 230 (80) | 5 (56) | |
| Yes | 62 (21) | 58 (20) | 4 (44) | |
| Trisomy 12, no. (%) | .05 | |||
| No | 245 (82) | 240 (83) | 5 (56) | |
| Yes | 52 (18) | 48 (17) | 4 (44) | |
| Del(13q), no. (%) | .75 | |||
| No | 145 (49) | 140 (49) | 5 (56) | |
| Yes | 152 (51) | 148 (51) | 4 (44) | |
| Del(11q), no. (%) | 1.00 | |||
| No | 214 (72) | 207 (72) | 7 (78) | |
| Yes | 83 (28) | 81 (28) | 2 (22) | |
| Del(17p), no. (%) | .03 | |||
| No | 177 (60) | 175 (61) | 2 (22) | |
| Yes | 120 (40) | 113 (39) | 7 (78) | |
| Complex karyotype, no. (%) | .01 | |||
| No | 119 (41) | 119 (42) | 0 (0) | |
| Yes | 172 (59) | 163 (58) | 9 (100) | |
| IGHV, no. (%) | .35 | |||
| Mutated | 53 (20) | 53 (21) | 0 (0) | |
| Unmutated | 212 (80) | 205 (79) | 7 (100) | |
Associations between near-tetraploidy and demographic, clinical, and molecular variables. Associations were tested using the Fisher exact for categorical variables and Wilcoxon rank-sum tests for continuous variables.